medigraphic.com
ISSN 1561-2988 (Print)

2020, Number 3

<< Back Next >>

Rev Cubana Farm 2020; 53 (3)

Stabilization of prostaglandin E1 (PGE1) for adjuvant treatment of intermittent claudication

Cortés MAE, Basto FSC, Pardo VS, Rojas CIK, Becerra HCE

Language: Spanish
References: 35
Page: 1-20
PDF size: 495.77 Kb.


ABSTRACT

Introduction: In the treatment of intermittent claudication some pharmacologic measures can be used and among them is prostaglandin which produces a vasodilatory effect in patients. The pharmacologic presentation´s way implies a big challenge to keep the molecule stable in the final product, since there are small impurities that can lead to undesired effects.
Objective: Analyze the stability of prostaglandina E1 for the adjuvant treatment of intermittent claudication in ampoules with onepointcut system and rubber stoppers.
Methods: It was made a review of the literature on clinical studies in which it was used the drug Alprostadil (pharmaceutical name of prostagladina E1) and that backed up its response´s capacity. Then, it was reviewed the pharmacotechnics and the pharmacodynamics of its action mechanisms and the relation between the concentration and the effect of it in the organism. Finally, the articles on conservation, transportation and management as thermolabile drug of frequent use in the hospital field were reviewed.
Conclusions: Prostaglandin E1 has proved to be an alternative and a complement to the non-invasive treatment of intermittent claudication. The specific treatment with Alprostadil in ampoules with onepointcut system offers according to the established protocol security to the patients and produces a notable improvement in the quality of life in occlusive arterial disease; in contrast to the use of rubber stoppers, due to the risks of contamination by the interaction among its components with the active molecule of the drug.


REFERENCES

  1. Urbano L, Portilla E, Muñoz W, Hofman A, Sierra-Torres CH. Prevalence and risk factors associated with peripheral arterial disease in an adult population from Colombia. Arch. Cardiol. Méx. 2018;88(2):107-115. DOI: 10.1016/j.acmx.2017.02.002

  2. Bluro IM. Conseso de enfermdad vascular periférica: Versión resumida. Rev. argent. cardiol. 2015 [acceso 12/03/2020];83(5):461-86. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1850-37482015000500021& lng=es

  3. Vargas Gembuel F, Vidal Patiño JW, Villafañe Blandón DA, Zúñiga Cerón LF, Saavedra Torres JS, Muñoz Ordoñez GW. Enfoque diagnóstico de la enfermedad arterial periférica de extremidad inferior." Morfolia. 2016;8(1). Disponible en: https://revistas.unal.edu.co/index.php/morfolia/article/view/57916

  4. Carmignano SM, Bellomo GR, d'Alessandro A, Mandolesi S, Sablone A, Barassi G, Saggini R. Rehabilitation of Patients with Peripheral Arterial Disease in IIA Stage According to Leriche-Fontaine. J Blood Lymph. 2016;6(147):2. DOI: 10.4172/2165-7831.1000147

  5. Bolaños Martínez I, Chaves Chaves A, Gallón Vanegas L, Morera Mario I, López Barquero H. Enfermedad arterial periférica en extremidades inferiores. Medicina. pierna. Costa Rica. 2019 [acceso 12/03/2020];36(1):84-90. Disponible en: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-00152019000100084&lng=en

  6. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ group. 2002; 24(7329): 71-86. DOI:10.1136/bmj.324.7329.71

  7. Galea Holmes MN, Weinman JA, Bearne LM. 'You can't walk with cramp!' A qualitative exploration of individuals' beliefs and experiences of walking as treatment for intermittent claudication. Journal of health psychology. 2017;22(2):255–265. DOI: 10.1177/1359105315600238

  8. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication (Cochrane Review). 2000. In: The Cochrane Library, 2, Oxford: Update Software. CD000990. DOI: 10.1002/14651858.CD000990

  9. Moreno DH, Cacione DG. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease). The Cochrane database of systematic reviews. 2018;(10):CD012794. DOI: 10.1002/14651858.CD012794.pub2

  10. Jansen SC, Hoorweg BB, Hoeks SE, van den Houten MM, Scheltinga MR, Teijink JA, Rouwet EV. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. Journal of vascular surgery. 2019;69(4):1293-1308.e2. DOI: 10.1016/j.jvs.2018.10.069

  11. Cheng Y, Liu M, Hu, H, Liu, D, Zhou, S. Development, optimization, and characterization of PEGylated nanoemulsion of prostaglandin E1 for long circulation. AAPS PharmSciTech. 2016;17(2):409-17. DOI: 10.1208 / s12249-015-0366-1

  12. Li Y, Tian H, Wu T. Prostaglandin E1 for diabetic neuropathy. The Cochrane database of systematic reviews. 2017;(1):CD006051. DOI: 10.1002/14651858.CD006051.pub2

  13. Badimon L. Vilajur G. Mecanismos de acción de los diferentes agentes antiplaquetarios. Rev Esp Cardiol Supl. 2013;13(B):8-15. DOI: 10.1016/S1131-3587(13)70074-8

  14. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). Journal of Vascular Surgery. 2000 [acceso 12/03/2020];31:S1-S296. Disponible en https://pubmed.ncbi.nlm.nih.gov/10666287/

  15. Conte SM, Vale PR. Peripheral arterial disease. Heart, Lung and Circulation. 2018;27(4):427-432. DOI: 10.1016/j.hlc.2017.10.014

  16. Robertson L, Andras A. Prostanoides para la claudicación intermitente. Cochrane Databse of Systematic Reviews 2013, Issue 4. art. No: CD000986. DOI: https://doi.org/10.1002/14651858.CD000986.pub3

  17. Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials. Journal for Vascular Diseases. 2013;42(5):331-39. DOI: 10.1024/0301-1526/a000298

  18. Karles-Ernotte AJ, Bermúdez-Posada A Rincón-Sánchez HM, Padilla-Castro AT, Drews-Elger K, Novoa-Leal M, et al. Efecto terapéutico del alprostadil en pacientes con isquemia crítica terminal de los miembros inferiores. Rev. Colomb. Cardiol. 2017;24(1):60-65. DOI: 10.1016/j.rccar.2016.04.014

  19. Winwood PJ, Arthur MJ. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin Liver Dis. 1993;13:50-59. DOI: 10.1055/s-2007-1007337

  20. Priano R, Hocht C, Oyola E, Capelli A. Estabilidad de prostaglandina E1 fraccionada en jeringas de polipropileno. Farm Hosp (Madrid). 2003 [acceso 12/03/2020];27(5):304-07. Disponible en: http://www.elsevier.es/es-revista-farmacia-hospitalaria-121-articulo-estabilidad-prostaglandina-e1-fraccionada-jeringas-13118835

  21. Rumzhum NN, Ammit AJ. Prostaglandin E2 induces expression of MAPK phosphatase 1 (MKP-1) in airway smooth muscle cells. European journal of pharmacology. 2016;782:1-5. DOI: 10.1016/j.ejphar.2016.04.041

  22. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 2001;21(3):185-210. DOI: 10.1002/med.1006

  23. Polster K. Bundesamt für Sicherheit im Gesundheitswesen. Public Assesment Report Scientific Discussion Pridax Alprostadil. Vienna: Springer; 2011 vol 8. p. 306-21. DOI: 10.1007/978-3-7091-0751-5

  24. Sanjuanelo A. Fiebre: actualización en el uso de antipiréticos. Precop, 2013 [acceso: 16/04/2020];11(4):26-35. Disponible en: https://es.scrib.com/document/441588877/Fiebre-actualizacion-en-antipireticos-2013

  25. Palmero D, Chavan E, Berger-Gryllaki M, Tolsa JF, Di Paolo ER Pannatier A, Sadeghipour F. Stability of prostaglandin E1 solutions stored in polypropylene syringes for continuous intravenous administration to newborns. Eur J Hosp Pharm. 2018;25(e2):e109-e114. DOI: 10.1136/ejhpharm-2017-001205

  26. Little J, Kurkela M, Sonka J, Jäntti S, Ketola R Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases. Journal of Lipid Research. 2004;45:1694-1703. DOI: 10.1194/jlr.M400103-JLR200

  27. Gotti R, Pomponio R, Andrisano V, Cavrini V. Analysis of prostaglandin E1 and related impurities by mixed aqueous-organic capillary electrophoresis. J. Separate Science. 2001;24:749-56. DOI: 10.1002/1615-9314(20010901)24:9<749::AID-JSSC749>3.0.CO;2-Z

  28. Gao Y, Hou R, Liu F, Cai R, Fang L, Peng C, Qi Y. Highly specific and sensitive immunoassay for the measurement of prostaglandin E2 in biological fluids.Bioanalysis. 2015;7(19): 2597-2607. DOI: 10.4155/bio.15.130

  29. Suzuki M, Koyama H, Ishii H, Kato K, Ögren M, Doi H. Green Process of Three-Component Prostaglandin Synthesis and Rapid 11C Labelings for Short-Lived PET Tracers. BoD–Books on Demand; 2018. DOI: 10.5772/intechopen.72868

  30. Chi Z, Wang ZP, Wang GY, Khan I, Chi ZM. Microbial biosynthesis and secretion of l-malic acid and its applications. Critical reviews in biotechnology. 2016;36(1):99-107. DOI: 10.3109/07388551.2014.924474

  31. Wharf C, London E. Background review for cyclodextrins used as excipients. 2014. EMA/CHMP/333892/2013; 2014 [acceso 16/04/2020]. Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf

  32. Heitz J, Bader S. An evidence-based approach to medication preparation for the surgical patient at risk for latex allergy: is it time to stop being stopper poppers? Journal of Clinical Anesthesia. 2010;22:477-83. DOI: 10.1016/j.jclinane.2009.12.006

  33. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice. 2004;1-56. [acceso 16/04/2020]. Disponible en: http://academy.gmp-compliance.org/guidemgr/files/Asept_Process_5882fnl.pdf

  34. Chromoy, G. Alergia al látex: el farmacéutico como agente de cambio; 2016. DOI: 10.13140/RG.2.2.23757.64480

  35. Carraretto A, Freitas E, David de Almeida C, Monteiro R. Ampollas de vidrio: Riesgos y beneficios. Revista Bras Anestesiol. 2011;61(4):280-284. DOI: 10.1590/S0034-70942011000400013




2020     |     www.medigraphic.com